Synergistic interaction between anti-p185(her-2) ricin a chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3334-3341

  Xu, Fengji ^a   Anthony Leadon, S ^b   Yu, Yinhua ^a   Boyer, Cinda M ^c   O'Briant, Kathy ^c   Ward, Kristine ^a   McWatters, Amanda ^a   Zhao, Xiaoguang ^c   Bae, Duk Soo ^c   DeSombre, Karen ^c   Zalutsky, Michael R ^c   Bast Jr , Robert C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOTOXIN; IODINE 131; RADIOISOTOPE; RICIN A;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; GENE EXPRESSION; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; COMBINED MODALITY THERAPY; DNA REPAIR; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOTOXINS; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RICIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0342646963     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Xu, F. J, Yu, Y. H., Bae, D. S., Zhao, X-G., Slade, C., Boyer, M., Bast, R. C., Jr., and Zalutsky, M. R. Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl. Med. Biol., 24: 451-460, 1997.
2. Pawson, R., Dyer, M. J., Barge, R., Matutes, E., Thornton, P. D., Emmet, E., Kluin-Nelemans, J. C., Fibbe, W. E., Willemze, R., and Catovsky, D. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol., 15: 2667-2672, 1997.
3. Davis, T. A., Maloney, D. G., Czerwinski, D. K., Liles, T. M., and Levy, R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood, 92: 1184-1190, 1998.
4. White, C. A., Larocca, A., and Grillo-Lopez, A. J. Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma. Pharm. Sci. Technol. Today, 2: 95-101, 1999.
5. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1966.
6. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Barelga, J., and Norton, L. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled Phase II trial. Proc. Am. Soc. Clin. Oncol., 17: 98, 1998.
7. Liu, S. Y., Eary, J. F., Peterdorf, S. H., Marin, D. G., Appelbaum, F. R., Matthews, D. C., Bush, S. A., Durack, L. D., Fisher, D. R., Gooley, T. A., Bernstein, I. D., and Press, O. W. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J. Clin. Oncol., 16: 3270-3278, 1998.
8. Kaminski, M. S., Zasandy, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., and Wahl, R. L. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.
9. Hird, V., Maraveyas, A., Snook, D., Dhokia, B., Soutter, W. P., Meares, C., Stewart, J. S., Mason, P., Lambert, H. E., and Epenetos, A. A. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer, 68: 403-406, 1993.
10. Lidor, Y. J., O'Briant, K. C., Xu, F. J., Hamilton, T. C., Ozols, R. F., and Bast, R. C., Jr. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells: mechanism of action. J. Clin. Investig., 92: 2440-2447, 1993.
11. Denardo, S. J., Kukis, D. L., Kroger, L. A., O'Donnell, R. T., Lamborn, K. R., Miers, L. A., DeNardo, D. G., Meares, C. F., and Denardo, G. L. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc. Natl. Acad. Sci. USA, 94: 4000-4004, 1997.
12. Slamon, D. J., Goldolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E, Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
13. Berchuck, A. Kamel, A. Whitaker, R. Kerns, B. Olt, G. Kinney, R. Soper, J. T. Dodge, R. Clarke-Pearson, D. L. Marks, P. Mckenzie, S. Yin, S., and Bast, R. C. Overexpression of HER-2/neu associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
14. Xu, F. J., Lupu, R., Rodriguez, G. C. Boyer, C. M., and Bast, R. C. Antibody-induced growth inhibtion is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER 2/neu) gene product p185. Int. J. Cancer, 53: 401-408, 1993.
15. EGFR-RTA. Clin. Cancer Res., 4: 2545-2550, 1998.
16. McKenzie, S. J., Marks, P. J., Lam, T., Margan, J., Panicali, D. L., Trimpe, K. L., and Carney, W. P. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene, 4: 543-548, 1989.
17. Bjorn, M. J., Ring, D., and Frankel, A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res., 45: 1214-1221, 1985.
18. Ring, D. B., Clark, R., and Saxena, A. Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. Mo1. Immunol., 28: 915-917, 1991.
19. Franke, P. J., and Speck, J. C., Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun., 80: 849-857, 1978.
20. Xu, F. J., Boyer, C. M., Bae, D. S., Wu, S., Greenwald, M., O'Briant, K., Yu, Y. H., Mills, G. B., and Bast, R. C. The tyrosine kinase activity of the c-erbB-2 gene product (pI85) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p I 85-ricin-A chain immunotoxin. Int. J. Cancer, 59: 242-247, 1994.
21. Johnson, E. A., and Brown, B. W., Jr. The Spearman estimator for serial dilution assay. Biometrics, 17: 79-88, 1961.
22. Berenbaum, M. C. Synergy, additivism and antagonism in immunosuppression: a critical review. Clin. Exp. Immunol., 28: 1-18, 1977.
23. Steel, G. G., and Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5: 85-91, 1979.
24. Press, W. H., Teukolsky S. A., Vetterling, S. A., and Flannery, B. P. Numerical recipes for FORTRAN, Ed. 2. Cambridge: Cambridge University Press, 1992.
25. Smith, C. A., Cooper, P. K., and Hanawalt, P. C. Measurement of repair replication by equilibrium sedimentation. In: E. C. Friedberg and P. C. Hanawalt (eds.), DNA Repair, A Laboratory Manual of Research Procedures, Vol. 1, pp. 289-305. New York: Marcel Dekker, Inc., 1981.
26. Boyer, C. M., Pusztai, L., Wiener, J. R., Xu, F. J., Dean, G. S., Bast, B. S., O'Briant, K. C., Greenwald, M., DeSombre, K., and Bast, R. C., Jr. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int. J. Cancer, 82: 525-531, 1999.
27. Bast, R. C., Jr., Frankel, A., and Zalutsky, M. R. Monoclonal serotherapy. In: J. F. Holland, E. Frei, III, R. C. Bast, Jr., D. Kufe, D. Morton, and R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 1245-1262. Baltimore: Williams & Wilkins, 1996.
28. Griffiths, G. D., Leek, M. D., and Gee, D. J. The toxic plant proteins ricin and abrin induce apoptotic changes in mammalian lymphoid tissues and intestine. J. Pathol., 151: 221-229, 1987.
29. Oda, T., Iwaoka, J., Komatsu, N., and Muramatsu, T. Involvement of N-acetylcysteine-sensitive pathways in ricin-induced apoptotic cell death in U937 cells. Biosci. Biotechnol. Biochem., 63: 341-348, 1999.
30. Keppler-Hafkemeyer, A., Brinkmann, U., and Pastan, I. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry, 37: 16934-16942, 1998.
31. Brinkman, U., Brinkman, E., Gallo, M., Scherf, U., and Pastan, I. Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis. Biochemistry, 35: 6891-6899, 1996.
32. Maier, L. A., Xu, F. J., Hester, S., Boyer, C. M., McKenzie, S., Bruskin, A. M., Argon, Y., Bast, R. C., Jr. Requirements for internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res., 51: 5361-5369, 1991.
33. Bast, R. C., Jr., Pusztai, L., Kerns, B. J., MacDonald, J. A., Jordan, P., Daly, L., Boyer, C. M., Mendelsohn, J., and Berchuck, A. Co-expression of the HER-2/neu (c-erbB-2) gene product (p185) and the epidermal growth factor receptor (p170) on epithelial ovarian cancers and normal tissues. Hybridoma, 17: 313-321, 1998.